Company / R&D Expense
IGC Pharma, Inc. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$3.7M
FY2025
5-year range
$929.0K / $3.7M
FY2021-FY2025
Trend
+5.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 3 consecutive years, from $929,000 in FY2022 to $4M in FY2025.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of +23.8%.
Improved from $2M to $4M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +57.9%
- 5-Year CAGR
- +23.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- IGC Pharma, Inc.'s r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +23.8%, indicating consistent growth.
- In FY2025, r&d expense increased 5.6% year-over-year.
- Lowest r&d expense in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.7M | +5.6% |
| FY2024 | $3.5M | +48.5% |
| FY2023 | $2.3M | +150.8% |
| FY2022 | $929.0K | -8.1% |
| FY2021 | $1.0M | -19.5% |
| FY2020 | $1.3M | +816.8% |
| FY2019 | $137.0K | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026